Aligos Therapeutics, Inc. Increase (Decrease) in Other Current Assets
Aligos Therapeutics, Inc. (ALGS) reported Increase (Decrease) in Other Current Assets of -$938.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-06
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2026-06-30 was -$620.00K.
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2026-03-31 was -$318.00K, a 316.33% decline year-over-year.
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2025-12-31 was $681.00K, a 130.07% increase year-over-year.
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for the quarter ending 2025-09-30 was -$587.00K.
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for fiscal 2025 was -$96.00K.
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for fiscal 2024 was -$216.00K.
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for fiscal 2023 was -$2.30M.
- Aligos Therapeutics, Inc. increase (decrease) in other current assets for fiscal 2022 was -$5.59M, a 169.30% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$620.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$938.00K 10-Q · filed 2026-08-06 | -$257.00K derived: sum of 3 quarters · filed 2026-08-06 | -$844.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$318.00K 10-Q · filed 2026-05-07 | $363.00K derived: sum of 2 quarters · filed 2026-05-07 | -$224.00K derived: sum of 3 quarters · filed 2026-05-07 | -$561.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $94.00K derived: sum of 2 quarters · filed 2026-03-05 | -$243.00K derived: sum of 3 quarters · filed 2026-08-06 | -$96.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$587.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$924.00K derived: sum of 2 quarters · filed 2026-08-06 | -$777.00K 10-Q · filed 2025-11-06 | -$481.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$337.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$190.00K 10-Q · filed 2026-08-06 | $106.00K derived: sum of 3 quarters · filed 2026-08-06 | -$64.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $147.00K 10-Q · filed 2026-05-07 | $443.00K derived: sum of 2 quarters · filed 2026-05-07 | $273.00K derived: sum of 3 quarters · filed 2026-05-07 | $135.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $296.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $126.00K derived: sum of 2 quarters · filed 2026-03-05 | -$12.00K derived: sum of 3 quarters · filed 2026-03-05 | -$216.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$170.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$308.00K derived: sum of 2 quarters · filed 2025-11-06 | -$512.00K 10-Q · filed 2025-11-06 | $663.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$138.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$342.00K 10-Q · filed 2025-08-06 | $833.00K derived: sum of 3 quarters · filed 2025-08-06 | $1.61M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$204.00K 10-Q · filed 2025-05-06 | $971.00K derived: sum of 2 quarters · filed 2025-05-06 | $1.75M derived: sum of 3 quarters · filed 2025-05-06 | -$415.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.95M derived: sum of 2 quarters · filed 2025-03-10 | -$211.00K derived: sum of 3 quarters · filed 2025-03-10 | -$2.30M 10-K · filed 2025-03-10 |
| 2023-09-30 | $779.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.39M derived: sum of 2 quarters · filed 2024-11-06 | -$3.47M 10-Q · filed 2024-11-06 | -$2.90M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$4.25M 10-Q · filed 2024-08-06 | -$3.68M derived: sum of 3 quarters · filed 2024-08-06 | -$4.25M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$2.09M 10-Q · filed 2024-05-07 | -$1.51M derived: sum of 2 quarters · filed 2024-05-07 | -$2.08M derived: sum of 3 quarters · filed 2024-05-07 | -$4.06M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $573.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.00K derived: sum of 2 quarters · filed 2024-03-12 | -$1.97M derived: sum of 3 quarters · filed 2024-03-12 | -$5.59M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$572.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$2.55M derived: sum of 2 quarters · filed 2023-11-02 | -$6.17M 10-Q · filed 2023-11-02 | $1.65M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$5.59M 10-Q · filed 2023-08-03 | $2.22M derived: sum of 3 quarters · filed 2023-08-03 | $2.26M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$3.62M 10-Q · filed 2023-05-04 | $4.19M derived: sum of 2 quarters · filed 2023-05-04 | $4.23M derived: sum of 3 quarters · filed 2023-05-04 | $4.73M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $7.85M derived: sum of 2 quarters · filed 2023-03-09 | $8.35M derived: sum of 3 quarters · filed 2023-03-09 | $8.07M 10-K · filed 2023-03-09 |
| 2021-09-30 | $38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $536.00K derived: sum of 2 quarters · filed 2022-11-02 | $259.00K 10-Q · filed 2022-11-02 | $3.32M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $498.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $221.00K 10-Q · filed 2022-08-04 | $3.28M derived: sum of 3 quarters · filed 2022-08-04 | $3.76M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$277.00K 10-Q · filed 2022-05-04 | $2.78M derived: sum of 2 quarters · filed 2022-05-04 | $3.27M derived: sum of 3 quarters · filed 2022-05-04 | $3.30M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.54M derived: sum of 2 quarters · filed 2022-03-10 | $3.58M derived: sum of 3 quarters · filed 2022-03-10 | $4.11M 10-K · filed 2022-03-10 |
| 2020-09-30 | $485.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $521.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.05M 10-Q · filed 2021-11-04 | $1.52M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $564.00K 10-Q · filed 2021-08-05 | $1.03M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $528.00K 10-Q · filed 2021-05-10 | $995.00K derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $1.03M 10-K · filed 2021-03-23 | ||
| 2019-09-30 | $563.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |